IL1A and Down syndrome: In the biggest review of pediatric patients with uAIDs, named syndrome of undifferentiated recurrent fever (SURF), IL-1 antagonists (mainly anakinra) used in 46 patients were effective in 74% of cases, superior to other non-biologic treatment options (79).